Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?

Hepatology International, Journal Year: 2023, Volume and Issue: 18(1), P. 168 - 178

Published: Dec. 21, 2023

Language: Английский

---

Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects

European Journal of Preventive Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors MASLD. The relationship two-way with MASLD found in up 75% patients T2DM. Importantly, associated increased cardiovascular diseases (CVD) such arrhythmia, atherosclerotic heart disease, failure, CVD-associated mortality. In addition, present a high prevalence major adverse cardiac events, calls for systematic surveillance CVD This review focuses on pathophysiology behind development MASLD, types complications, morbidity survival, suggestions evaluation

Language: Английский

---

Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease

Hepatoma Research, Journal Year: 2024, Volume and Issue: 10, P. 16 - 16

Published: Jan. 1, 2024

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic disease. This term does not describe pathogenetic mechanisms and complications associated with NAFLD. The new definition, Metabolic Dysfunction-associated Steatotic Liver (MASLD), emphasizes relationship between NAFLD cardiometabolic comorbidities. Cardiovascular features, such as arterial hypertension atherosclerosis, are frequently patients MASLD. Furthermore, these have a high risk developing neoplastic diseases, primarily hepatocellular carcinoma, but also extrahepatic tumors, esophageal, gastric, pancreatic cancers. Moreover, several studies showed correlation MASLD endocrine imbalance gut microbiota, systemic inflammation, obesity, insulin resistance play key role in development complications. narrative review aims to clarify evolution from nomenclature evaluate its

Language: Английский

---

Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease

Nutrire, Journal Year: 2025, Volume and Issue: 50(1)

Published: Jan. 6, 2025

Language: Английский

---

Golgi protein 73: charting new territories in diagnosing significant fibrosis in MASLD: a prospective cross-sectional study

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 13, 2025

To explore the correlation between serum Golgi protein 73 (GP73) levels and degree of fibrosis in Metabolic dysfunction associated steatotic liver disease (MASLD); to establish a non-invasive diagnostic algorithm based on GP73 elasticity. This is prospective cross-sectional study, including 228 patients diagnosed with MASLD from May 2018 January 2024 at two tertiary hospitals. Clinical data hepatic pathological features were assessed. A new was conducted after logistic regression. Receiver Operating Characteristic (ROC) curve used compare its performance traditional models. Significant 37.2% (85/228) patients. Serum markedly higher significant than those without (128 ng/mL v.s 46 ng/mL, p< 0.001). independently predicted (adjusted odds ratio, aOR 1.028, developed area under ROC (AUC) 0.840 that Fibrosis index-4 (p< an independent risk factor for MASLD, GFA (GP73-Fibroscan-Age) model has good efficacy fibrosis.

Language: Английский

---

Impact of microplastics and nanoplastics on liver health: Current understanding and future research directions

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(9), P. 1011 - 1017

Published: March 5, 2024

With continuous population and economic growth in the 21

Language: Английский

---

Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)—A Randomized Pilot Trial

Nutrients, Journal Year: 2024, Volume and Issue: 16(11), P. 1571 - 1571

Published: May 22, 2024

Several studies show that gut microbiotas in patients with nonalcoholic fatty liver disease (NAFLD) differ from those a healthy population, suggesting this alteration plays role NAFLD pathogenesis. We investigated whether prebiotic administration affects fat content and/or liver-related and metabolic parameters. Patients syndrome (age: 50 ± 11; 79% men) were randomized to receive either 16 g/day of (ITFs-inulin-type fructans) (n = 8) or placebo (maltodextrin) 11) for 12 weeks. instructed maintain stable weight throughout the study. Liver (measured by H1MRS), fecal microbiota, metabolic, inflammatory, parameters determined before after intervention. Fecal samples who received had an increased Bifidobacterium (p 0.025), which was not observed placebo. However, baseline end-of-study contents did change significantly groups, neither function tests' inflammatory mediators, including fibroblast growth factor-19 lipopolysaccharide-binding protein. Body remained both groups. These findings suggest treatment without reduction is insufficient improve NAFLD.

Language: Английский

---

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis

Annals of Hepatology, Journal Year: 2023, Volume and Issue: 29(2), P. 101174 - 101174

Published: Oct. 29, 2023

Nonalcoholic fatty liver disease (NAFLD) is a chronic with high prevalence worldwide and poses serious harm to human health. There growing evidence suggesting that the administration of specific supplements or nutrients may slow NAFLD progression. Silymarin hepatoprotective extract milk thistle, but its efficacy in remains unclear. Relevant studies were searched PubMed, Embase, Cochrane Library, Web Science, clinicaltrails.gov, China National Knowledge Infrastructure screened according eligibility criteria. Data analyzed using Revman 5.3. Continuous values dichotomous pooled standard mean difference (SMD) odds ratio (OR). Heterogeneity was evaluated Cochran's Q test (I2 statistic). A P<0.05 considered statistically significant. total 26 randomized controlled trials involving 2,375 patients included this study. Administration silymarin significantly reduced levels TC (SMD[95%CI]=-0.85[-1.23, -0.47]), TG (SMD[95%CI]=-0.62[-1.14, -0.10]), LDL-C (SMD[95%CI]=-0.81[-1.31, -0.31]), FI (SMD[95%CI]=-0.59[-0.91, -0.28]) HOMA-IR (SMD[95%CI]=-0.37[-0.77, 0.04]), increased level HDL-C (SMD[95%CI]=0.46[0.03, 0.89]). In addition, attenuated injury as indicated by decreased ALT (SMD[95%CI]=-12.39[-19.69, -5.08]) AST (SMD[95% CI]=-10.97[-15.51, -6.43]). The index (SMD[95%CI]=-6.64[-10.59, -2.69]) score (SMD[95%CI]=-0.51[-0.69, -0.33]) also decreased. Liver histology intervention group revealed improved hepatic steatosis (OR[95%CI]=3.25[1.80, 5.87]). can regulate energy metabolism, attenuate damage, improve patients. However, effects will need be confirmed further research.

Language: Английский

---

Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 13, 2025

Introduction Evaluation of the ultrasound attenuation coefficient is widely used in diagnosis steatotic liver disease (SLD). US steatometry with real-time measurement (ACM) an imaging tool that can replace and surpass B-mode improve noninvasive SLD. Aim To evaluate intra- interobserver variability ACM for assessment Materials methods A single-center cross-sectional study was conducted at Kyiv City Clinical Endocrinology Center. We examined 52 patients (25 men 27 women) a mean age 53.2 ± 4.73 years. were performed on Soneus P7 system (Ultrasign, Ukraine). Examinations by 2 radiologists 28 (expert 1) 17 2) years experience 4 general practitioners (GPs) without (nonexperts 1–4). The training GPs mastering only 60 min due to steatophantom. Each doctor 5 measurements each patient. inter- intraobserver results determined using intraclass correlation (ICC) 95% confidence interval (95% CI). Results overall after days examination as follows: expert 1–0.958 CI 0.938–0.974); 2–0.936 0.905–0.980); nonexpert 1–0.891 0.843–0.929); 2–0.915 0.876–0.945); 3–0.927 0.893–0.953); 4–0.880 0.827–0.927). Interobserver final timepoint (day 5) between experts 1 2, 0.942 0.898–0.967); nonexperts 1–4 overall, 0.871 0.800–0.921); 0.922 0.883–0.951). Conclusion Real-time informative, simple method excellent reproducible population early staging simplicity technology allows master technique within min. be effectively employed screening, enabling timely identification management MASLD.

Language: Английский

---

Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease

World Journal of Hepatology, Journal Year: 2025, Volume and Issue: 17(4)

Published: April 25, 2025

In this article, we discuss the recently published article by Soni et al. This study explores effectiveness of a comprehensive digital health program, RESET care, which integrates personalized dietary plans, structured exercise, and cognitive behavioral therapy delivered through mobile app equipped with Internet Things devices such as body composition analyzers smartwatches. Metabolic dysfunction-associated liver disease (MASLD), global burden affecting approximately 25% population, demands sustainable lifestyle modifications its primary management strategy. The reports that 100% participants in intervention group (diet + exercise therapy) achieved weight reduction ≥ 7% (6.99 ± 2.98 kg, 7.00% 3.39%; P = 0.002), clinically significant threshold for MASLD improvement. addition, showed mean 6.99 kg (101.10 17.85 vs 94.11 17.38, < 0.001) mass index 2.18 kg/m² (32.90 3.02 30.72 3.41, 0.001). These results underscore potential platforms to provide scalable, evidence-based solutions treatment MASLD. While these highlight scalable MASLD, small sample size short duration follow-up limit generalizability results. Future large-scale, long-term trials are needed confirm sustained benefits, cost-effectiveness, broader applicability. letter contextualizes within evolving landscape emphasizes clinical implications integrating technologies into standard care.

Language: Английский

---